(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Southern Californians, your health insurance costs could rise in 2026 - 2Manual for Tracking down Spending plan Agreeable Travel Objections
- 3Vote in favor of the wide open action that revives your brain and soul!
- 4Understanding Various Sorts of Financial balances: An Extensive Outline
- 5Getting Your Youngsters' Future: Grasping Legacy Regulations
- Google's proposed data center in orbit will face issues with space debris in an already crowded orbit
- US FDA panel to weigh bid to market nicotine pouches as lower-risk than cigarettes
- Vote in favor of Your #1 BWM Vehicles
- A definitive Bike Standoff: Decision in favor of Your Number one Ride
- Six Flags Opens the Tallest, Fastest and Longest Roller Coaster in the World
- Top notch Remote Earphones for Audiophiles
- MacArthur Foundation awards $100M to outbreak surveillance network, a boost amid global health cuts
- PHOTO ESSAY: Summer camp for kids with autoimmune diseases
- Ancient eggshells shed new light on crocodiles that hunted prey from trees
